Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Non-cash Items: 2015-2025

Historic Non-cash Items for Adma Biologics (ADMA) over the last 8 years, with Sep 2025 value amounting to $2.8 million.

  • Adma Biologics' Non-cash Items rose 9.91% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year increase of 9.91%. This contributed to the annual value of $68.1 million for FY2024, which is 664.16% up from last year.
  • As of Q3 2025, Adma Biologics' Non-cash Items stood at $2.8 million, which was down 75.15% from $11.1 million recorded in Q2 2025.
  • Adma Biologics' 5-year Non-cash Items high stood at $68.1 million for Q4 2024, and its period low was $35,935 during Q4 2021.
  • Over the past 3 years, Adma Biologics' median Non-cash Items value was $6.7 million (recorded in 2023), while the average stood at $12.1 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first skyrocketed by 21,161.28% in 2022, then plummeted by 47.80% in 2024.
  • Adma Biologics' Non-cash Items (Quarterly) stood at $35,935 in 2021, then soared by 21,161.28% to $7.6 million in 2022, then increased by 16.67% to $8.9 million in 2023, then surged by 664.16% to $68.1 million in 2024, then climbed by 9.91% to $2.8 million in 2025.
  • Its Non-cash Items was $2.8 million in Q3 2025, compared to $11.1 million in Q2 2025 and $12.7 million in Q1 2025.